Abstract Library

#4639 Prevalence and characteristics of incidental NET of the Meckel’s diverticula: Retrospective cohort study at a tertiary centre

Introduction: Meckel’s diverticulum is a rare finding in adults but can harbour malignancies such as leiomyosarcoma or neuroendocrine tumours (NET). The clinical presentation and tumour characteristics, including grading, have shown high variability in recent studies for NET.

Conference:

Presenting Author: Berckenhagen L

Authors: Berckenhagen L, Weidemann S, Amin T, Ritter A, Poppinga J,

Keywords: Meckel’s diverticula, incidental NET, acute abdomen, lower GI-bleeding,

#4499 Impact of early molecular tumour board inclusion on treatment outcomes in neuroendocrine neoplasms: A retrospective double-centre study

Introduction: The treatment of neuroendocrine neoplasms (NENs) is particularly challenging due to the limited availability of standard therapies. While personalised approaches are revolutionising many areas of oncology, their progress in the field of NENs has been comparatively slower. The integration of molecular tumour boards (MTBs) into clinical practice represents a major advance in oncology, even for rare entities such as NENs.

Conference:

Presenting Author: Klaas L

Authors: Barsch M, Graessel L, Metzger P, Klaas L, Schulz L,

Keywords: Neuroendocrine neoplasm, Molecular Tumour Board, personalised medicine, precision oncology, targeted therapy,

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),

#4281 Automated (artificial intelligence) vs. manual evaluation of the somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms: A pilot study

Introduction: Digital image analysis methods are currently being equipped with artificial intelligence (AI). Various AI applications are already in use to determine Ki-67. To date, there is no specialised AI application available to determine the somatostatin-receptor 2A (SSTR2A).

Conference:

Presenting Author:

Authors: Kaemmerer D, Lupp A, Klöppel G, Ayako I, Kasajima A,

Keywords: artificial intelligence, Ki-67, SSTR2A, usability, neuroendocrine neoplasm,

#3954 Comparison of transarterial embolisation (TAE) or chemoembolisation (TACE) using streptozotocin (STZ) and biomarker study in patients with metastatic neuroendocrine tumors (NET)

Introduction: We compared TACE and TAE in patients with pancreatic (pNET) or small-intestine NET (siNET) and explored the role of biomarkers related to alkylating agents (O6-methylguanine-methyltransferase [MGMT], alkylpurine–DNA–N-glycosylase [APNG]) or hypoxia (Carbonic anhydrase IX [CAIX]).

Conference:

Presenting Author: de Mestier L

Authors: Vedie A, Dioguardii Burgioo M, Matteini F, Akez M, Hentic O,

Keywords: transarterial embolization, chemoembolization, metastatic neuroendocrine tumor, biomarker,